The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 2025 financial results. Among other items, Fulgent provided lower-than-expected guidance for 2026, “reflect[ing] the impact of [its] largest customer moving a significant volume of its work in-house[.]” On this news, the price of Fulgent shares declined by $9.43 per share, or approximately 38.1%, from $24.76 per share on February 26, 2026 to close at $15.33 on February 27, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Fulgent securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260325365845/en/